| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial †
|
Eigentler, T.K.
|
|
|
27 |
8 |
p. 1625-1632
|
artikel
|
| 2 |
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial †
|
Clement, P.M.
|
|
|
27 |
8 |
p. 1585-1593
|
artikel
|
| 3 |
Anti-PD-1-associated organizing pneumonia in a responding melanoma patient
|
Fiset, P.O.
|
|
|
27 |
8 |
p. 1649-1650
|
artikel
|
| 4 |
A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment
|
Calura, E.
|
|
|
27 |
8 |
p. 1511-1519
|
artikel
|
| 5 |
A tribute to biologics in advanced colorectal cancer treatment
|
Sobrero, A.
|
|
|
27 |
8 |
p. 1372-1374
|
artikel
|
| 6 |
Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker
|
Da Silva, F.
|
|
|
27 |
8 |
p. 1651-1652
|
artikel
|
| 7 |
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
|
Moschetta, M.
|
|
|
27 |
8 |
p. 1449-1455
|
artikel
|
| 8 |
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial) †
|
Michl, M.
|
|
|
27 |
8 |
p. 1565-1572
|
artikel
|
| 9 |
Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory
|
Sartore-Bianchi, A.
|
|
|
27 |
8 |
p. 1456-1466
|
artikel
|
| 10 |
Consensus on precision medicine for metastatic cancers: a report from the MAP conference
|
Swanton, C.
|
|
|
27 |
8 |
p. 1443-1448
|
artikel
|
| 11 |
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer
|
Paz-Ares, L.
|
|
|
27 |
8 |
p. 1573-1579
|
artikel
|
| 12 |
Current management of newly diagnosed acute promyelocytic leukemia
|
Cicconi, L.
|
|
|
27 |
8 |
p. 1474-1481
|
artikel
|
| 13 |
Editorial board
|
|
|
|
27 |
8 |
p. ii-iii
|
artikel
|
| 14 |
Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial
|
Keefe, S.M.
|
|
|
27 |
8 |
p. 1579-1585
|
artikel
|
| 15 |
ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016
|
Dittrich, C.
|
|
|
27 |
8 |
p. 1378-1381
|
artikel
|
| 16 |
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
|
Van Cutsem, E.
|
|
|
27 |
8 |
p. 1386-1422
|
artikel
|
| 17 |
ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe
|
Cherny, N.
|
|
|
27 |
8 |
p. 1423-1443
|
artikel
|
| 18 |
Factors associated with depression and anxiety symptoms in family caregivers of patients with incurable cancer †
|
Nipp, R.D.
|
|
|
27 |
8 |
p. 1607-1612
|
artikel
|
| 19 |
How to report toxicity associated with targeted therapies?
|
Cabarrou, B.
|
|
|
27 |
8 |
p. 1633-1638
|
artikel
|
| 20 |
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
|
Kim, J.M.
|
|
|
27 |
8 |
p. 1492-1504
|
artikel
|
| 21 |
International cancer seminars: a focus on kidney cancer
|
Scelo, G.
|
|
|
27 |
8 |
p. 1382-1385
|
artikel
|
| 22 |
Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
|
Rustin, G.J.S.
|
|
|
27 |
8 |
p. 1365-1366
|
artikel
|
| 23 |
Necitumumab in squamous non-small-cell lung cancer: how to move forward?
|
Garrido, Pilar
|
|
|
27 |
8 |
p. 1374-1376
|
artikel
|
| 24 |
P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer
|
Jagadeeshan, S.
|
|
|
27 |
8 |
p. 1546-1556
|
artikel
|
| 25 |
PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer
|
Sclafani, F.
|
|
|
27 |
8 |
p. 1557-1565
|
artikel
|
| 26 |
Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer †
|
Argiris, A.
|
|
|
27 |
8 |
p. 1594-1600
|
artikel
|
| 27 |
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab †
|
Loibl, S.
|
|
|
27 |
8 |
p. 1519-1525
|
artikel
|
| 28 |
PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum
|
Goel, S.
|
|
|
27 |
8 |
p. 1368-1372
|
artikel
|
| 29 |
Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy
|
Pivot, X.
|
|
|
27 |
8 |
p. 1525-1531
|
artikel
|
| 30 |
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
|
Lindemann, K.
|
|
|
27 |
8 |
p. 1505-1510
|
artikel
|
| 31 |
Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline
|
Ramanathan, R.K.
|
|
|
27 |
8 |
p. 1647-1648
|
artikel
|
| 32 |
Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways
|
Doherty, M.
|
|
|
27 |
8 |
p. 1644-1646
|
artikel
|
| 33 |
Prognostic pathways in early-stage ovarian cancer: can gene expression transcend histological subtype?
|
McNeish, I.A.
|
|
|
27 |
8 |
p. 1366-1368
|
artikel
|
| 34 |
Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology?
|
Paydas, S.
|
|
|
27 |
8 |
p. 1650-1651
|
artikel
|
| 35 |
Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study
|
Suzuki, K.
|
|
|
27 |
8 |
p. 1601-1606
|
artikel
|
| 36 |
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
|
Yamazaki, K.
|
|
|
27 |
8 |
p. 1539-1546
|
artikel
|
| 37 |
Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients
|
Patel, J.D.
|
|
|
27 |
8 |
p. 1612-1619
|
artikel
|
| 38 |
Reply to ‘Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents’ by Saad and Buyse
|
van Halteren, H.K.
|
|
|
27 |
8 |
p. 1652-1653
|
artikel
|
| 39 |
Response to the letter to the editor ‘Reply to “Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents” by H. K. van Halteren’
|
Saad, E.D.
|
|
|
27 |
8 |
p. 1653
|
artikel
|
| 40 |
Significance of the prognostic stratification of extranodal extension in colorectal cancer
|
Luchini, C.
|
|
|
27 |
8 |
p. 1647
|
artikel
|
| 41 |
Table of Contents
|
|
|
|
27 |
8 |
p. iv-vii
|
artikel
|
| 42 |
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic
|
Winter, C.
|
|
|
27 |
8 |
p. 1532-1538
|
artikel
|
| 43 |
Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
|
Pitt, J.M.
|
|
|
27 |
8 |
p. 1482-1492
|
artikel
|
| 44 |
The challenge to one-course carboplatin in seminoma clinical stage 1
|
Dieckmann, K.-P.
|
|
|
27 |
8 |
p. 1648-1649
|
artikel
|
| 45 |
The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma
|
Wirth, T.C.
|
|
|
27 |
8 |
p. 1467-1474
|
artikel
|
| 46 |
The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortium
|
Hashim, D.
|
|
|
27 |
8 |
p. 1619-1625
|
artikel
|
| 47 |
The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies
|
Cirkel, G.A.
|
|
|
27 |
8 |
p. 1638-1643
|
artikel
|
| 48 |
Where next in kidney cancer?
|
Powles, T.
|
|
|
27 |
8 |
p. 1376-1377
|
artikel
|
Tijdschrift beschrijving